Side effects guide

Melanotan-1 Side Effects

Alpha-MSH analog (afamelanotide)

In the EPP trials and the SCENESSE label, the most common effects were implant-site reactions, nausea, headache, fatigue, and skin darkening (increased pigmentation). Most were mild to moderate in the studied implant setting.[1][2]

Reviewed for accuracy · Last reviewed July 8, 2026

Reported side effects

COMMONImplant-site reactions · Nausea · Headache · Skin darkening · Fatigue
LESS COMMONDizziness · Darkening of moles/freckles · Serious hypersensitivity (rare)

A specific concern with melanocortin tanning agents is that they can darken and change pre-existing moles and freckles. The approved label recommends a full-body skin examination twice a year to monitor pigmented lesions, and any mole that changes in size, shape, or color warrants medical review.

Rare but serious hypersensitivity reactions, including anaphylaxis, have been reported. These safety data come from the approved implant used in EPP; the safety of unregulated injectable tanning use is not characterized by any comparable evidence, so effects there are less predictable, not safer.

Seek medical attention ifYou notice signs of an allergic reaction, or a mole that changes in size, shape, or color. Melanocortin agents can darken and alter existing moles, so skin should be monitored.

Managing side effects

Skin monitoring is the main practical step: a twice-yearly full-body skin check, and prompt review of any changing mole. Nausea and headache reported in trials were generally mild to moderate.

FAQ

What are the most common side effects?In the EPP trials and label, implant-site reactions, nausea, headache, fatigue, and skin darkening were most common, generally mild to moderate in the studied implant setting.
Can Melanotan-1 affect moles or skin cancer risk?It can darken and change existing moles and freckles, which is why twice-yearly full-body skin exams are recommended. Report any mole that changes in size, shape, or color to a clinician.

References

  1. Afamelanotide for Erythropoietic ProtoporphyriaNew England Journal of Medicine · 2015 · PMID 26132941 · DOI 10.1056/NEJMoa1411481
  2. SCENESSE (afamelanotide) implant: DailyMed labelDailyMed (U.S. National Library of Medicine) · current · DailyMed setid 94f53286-11dd-7fbb-e053-2a95a90a7c48
Researching this compound? PepHub can help you keep notes and sources in one place.Learn more →

This page is an independent educational reference and is not medical advice. The approval described applies only to the SCENESSE implant for erythropoietic protoporphyria, not to tanning use. Talk to a doctor before starting any compound.